When it came to deciding where drug giant AstraZeneca would expand its work making biologic medicines, there was no question the project would happen in Maryland, the company's top U.S. official said this Wednesday. "I don't know where else we would go in terms of innovation," said Paul Hudson, AstraZeneca's U.S. president as the company unveiled progress on its $200 million expansion in Frederick.